Quantifying HLA-specific antibodies in patients undergoing desensitization

Current Opinion in Organ Transplantation

Volumn 16, Issue 4, 2011, Pages 410-415

  Zachary, Andrea ^a   Reinsmoen, Nancy L ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

crossmatch; desensitization; donor HLA specific antibody; IVIg; solid phase immunoassays

Indexed keywords

BORTEZOMIB; ECULIZUMAB; HLA ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN M; PANEL REACTIVE ANTIBODY; RITUXIMAB; THYMOCYTE ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIBODY SCREENING; ANTIBODY SPECIFICITY; B LYMPHOCYTE; BLOOD GROUP ABO SYSTEM; COMPLEMENT DEPENDENT CYTOTOXICITY; DESENSITIZATION; DRUG MEGADOSE; DRUG MONITORING; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT REJECTION; HISTOCOMPATIBILITY; HUMAN; IMMUNOASSAY; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; ORGAN DONOR; ORGAN TRANSPLANTATION; PLASMAPHERESIS; REVIEW; SOLID PHASE IMMUNOASSAY; T LYMPHOCYTE;

DESENSITIZATION, IMMUNOLOGIC; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOASSAY; ISOANTIBODIES; ORGAN TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; SOLID PHASE EXTRACTION; TREATMENT OUTCOME;

EID: 80051788383     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32834899b8     Document Type: Review

References (26)

1. Zachary AA, Eng HS. Desensitization: Achieving immune detente. Tissue Antigens 2010; 77:3-8.
2. Jordan SC, Peng A, Vo AA. Therapeutic strategies in management of the highly HLA-sensitized and ABO-incompatible transplant recipients. Contrib Nephrol 2009; 162:13-26.
3. Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 15:1095-1102. This study shows improved rates of transplant for sensitized renal recipients following IVIg/R therapy with acceptable AMR and survival rates.
4. Warren DS, Montgomery RA. Incompatible kidney transplantation: Lessons from a decade of desensitization and paired kidney exchange. Immunol Res 2010; 47:257-264.
5. Zachary AA, Leffell MS. Detecting and monitoring human leukocyte antigenspecific antibodies. Hum Immunol 2008; 69:591-604.
6. Tait BD, Hudson F, Brewin G, et al. Solid phase HLA antibody detection technology-challenges in interpretation. Tissue Antigens 2010; 76:87-95.
7. Batal I, Zeevi A, Lunz JG, et al. Antihuman leukocyte antigen-specific antibody strength determined by complement-dependent or solid-phase assays can predict positive donor-specific crossmatches. Arch Pathol Lab Med 2010; 134:1534-1540.
8. Lindemann M, Nyadu B, Heinemann FM, et al. High negative predictive value of an amplified flow cytometry crossmatch before living donor kidney transplantation. Hum Immunol 2010; 71:771-776.
9. Morris GP, Phelan DL, Jendrisak MD, Mohanakumar T. Virtual crossmatch by identification of donor-specific antihuman leukocyte antigen antibodies by solid-phase immunoassay: A 30-month anal7ysis in living donor kidney transplantation. Hum Immunol 2010; 71:268-273.
10. Tambur AR, Ramon DS, Kaufman DB, et al. Perception versus reality?: Virtual crossmatch-how to overcome some of the technical and logistic limitations. Am J Transplant 2009; 9:1886-1893.
11. Zachary AA, Sholander JT, Houp JA, Leffell MS. Using real data for a virtual crossmatch. Hum Immunol 2009; 70:574-579.
12. Leffell MS, Zachary AA. The role of the histocompatibility laboratory in desensitization for transplantation. Curr Opin Organ Transplant 2009; 14:398-402.
13. Reinsmoen NL, Lai CH, Vo A, et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008; 86:820-825.
14. Zachary AA, Lucas DP, Detrick B, Leffell MS. Naturally occurring interference in Luminex assays for HLA-specific antibodies: Characteristics and resolution. Hum Immunol 2009; 70:496-501. This study describes the effect of interfering factors on the specificity and strength of HLA antibodies and provides methods for overcoming the problem.
15. Badders JL, Houp JA, Sholander JT, et al. Consideration in interpreting solid phase antibody data. Hum Immunol 2010; 71:S18.
16. Vo A, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359:242-251. (Pubitemid 352008439)
17. Lai CH, Cao K, Ong G, et al. Antibody testing strategies for deceased donor kidney transplantation after immunomodulatory therapy. Transplantation 2011 [Epub head of print]. This study defines the antibody levels following IVIg/R that allow successful transplantation with deceased donors with low risk for AMR. This approach provides patients broadly sensitized to HLA with an opportunity for deceaseddonor transplantation.
18. Locke JE, Zachary AA, Warren DS, et al. Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. Am J Transplant 2009; 9:2136-2139.
19. Kraus ES, Parekh RS, Oberai P, et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: Incidence and correlations. Am J Transplant 2009; 9:1826-1834.
20. Gloor JM, Winters JL, Cornell LD, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010; 10:582-589.
21. Magee CC, Felgueiras J, Tinckam K, et al. Renal transplantation in patients with positive lymphocytotoxicity crossmatches: One center's experience. Transplantation 2008; 86:96-103.
22. Zachary AA, Montgomery RA, Leffell MS. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum Immunol 2005; 66:364-370. (Pubitemid 40615791)
23. Phelan D, Mohanakumar T, Ramachandran S, Jendrisak MD. Living donor renal transplantation in the presence of donor-specific human leukocyte antigen antibody detected by solid-phase assay. Hum Immunol 2009; 70:584-588.
24. Reithmüller S, Ferrari-Lacraz S, Müller MK, et al. Donor-specific antibody levels ant three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. Transplantation 2010; 90:160-167.
25. Aubert V, Venets JP, Pantaleo G, Pascual M. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant.HumImmunol 2009; 70:580-583.
26. Vlad G, Ho EL, Vasilescu ER, Colovai AI. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Hum Immunol 2009; 70:589-594.